HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EFSA Considering New CBD Toxicity Data While Clock-Stop Causes Industry ‘Economic Harm’

Executive Summary

The European Food Safety Authority is evaluating new reproductive and developmental toxicity data published since it paused CBD novel food applications last year due to safety concerns, according to food law consultancy, Legal Foods.

You may also be interested in...

10mg CBD Per Day – UK Food Regulator Sets ‘Provisional’ Acceptable Daily Limit

The UK Food Standards Agency has issued new advice aimed at consumers warning them not to take more than 10mg CBD per day, an acceptable daily intake level significantly lower than the agency's previous ADI of 70mg per day. However, CBD brand owners should not reformulate their products, Canna Consultants warns, as this would be a breach of FSA's conditions for remaining on the market. 

EU Court Shoots Down TiO2 Hazard Classification, Opening Door For Future Challenges

Titanium dioxide stakeholders argued successfully in the Court of Justice of the European Union that TiO2’s hazard classification in 2020 under the CLP was based on shoddy science and a flawed interpretation of EU law. The industry win comes as the European Commission is finalizing a regulation to establish new CLP hazard classes, including for endocrine disruptors.

EU CBD Novel Food Applications On Hold As EFSA Considers Health Risks

All European Union CBD novel food applications have been paused by EFSA after its Panel on Nutrition, Novel Foods and Food Allergens raised concerns about the ingredient's safety, pointing in a wide-ranging scientific literature review to a number of data gaps related to bioavailability, liver damage, gastrointestinal issues and possible negative impacts on pregnancy and reproductive health.  


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts